Journal: PLoS ONE

Article Title: Prospective evaluation of two screening methods for molecular testing of metastatic melanoma: Diagnostic performance of BRAF V600E immunohistochemistry and of a NRAS-BRAF fully automated real-time PCR-based assay

doi: 10.1371/journal.pone.0221123

Figure Lengend Snippet: Comparison of BRAF and NRAS results by allele specific amplification, Sanger sequencing, IHC and Idylla testing.

Article Snippet: Slides were stained with anti-BRAF V600E mutant-specific antibody (clone VE1, dilution 1:200, pH9, Eurobio) [ ] .

Techniques: Comparison, Amplification, Sequencing, Mutagenesis

Journal: PLoS ONE

Article Title: Prospective evaluation of two screening methods for molecular testing of metastatic melanoma: Diagnostic performance of BRAF V600E immunohistochemistry and of a NRAS-BRAF fully automated real-time PCR-based assay

doi: 10.1371/journal.pone.0221123

Figure Lengend Snippet: A. Control of samples found positive for BRAF mutation by ASA/Sequencing but negative by IHC. B. Control of samples found negative for BRAF mutation by ASA/sequencing and positive by IHC (wrong chromogen used). C. Control of samples found positive for NRAS mutation by sequencing but negative by Idylla. Yellow dots correspond to wild type DNA copies ( BRAF , panels A and B; NRAS , panel C). Green dots correspond to mutated DNA copies ( BRAF V600E, panels A and B; NRAS Q61R, panel C). Grey dots correspond to empty wells.

Article Snippet: Slides were stained with anti-BRAF V600E mutant-specific antibody (clone VE1, dilution 1:200, pH9, Eurobio) [ ] .

Techniques: Control, Mutagenesis, Sequencing

Journal: PLoS ONE

Article Title: Prospective evaluation of two screening methods for molecular testing of metastatic melanoma: Diagnostic performance of BRAF V600E immunohistochemistry and of a NRAS-BRAF fully automated real-time PCR-based assay

doi: 10.1371/journal.pone.0221123

Figure Lengend Snippet: Discordant genotyping results.

Article Snippet: Slides were stained with anti-BRAF V600E mutant-specific antibody (clone VE1, dilution 1:200, pH9, Eurobio) [ ] .

Techniques: Digital PCR

Journal: Journal of Translational Medicine

Article Title: Papillary thyroid cancer organoids harboring BRAF V600E mutation reveal potentially beneficial effects of BRAF inhibitor-based combination therapies

doi: 10.1186/s12967-022-03848-z

Figure Lengend Snippet: List of drugs used in this study

Article Snippet: Primary antibodies against CK19 (1:200, Cat. No. Kit-0030, Maixin Biotech, China), galectin-3 (1:500, Cat. No. ab76245, Abcam), Ki-67 (1:200, cat. no. ab16667, Abcam), and BRAF (V600E mutant) (1:200, Cat. No. 29002, Cell Signaling Technology) were applied to the sections and incubated overnight at 4 °C.

Techniques: DNA Synthesis

Journal: Journal of Translational Medicine

Article Title: Papillary thyroid cancer organoids harboring BRAF V600E mutation reveal potentially beneficial effects of BRAF inhibitor-based combination therapies

doi: 10.1186/s12967-022-03848-z

Figure Lengend Snippet: Establishment of patient-derived PTC organoids harboring BRAF V600E mutation or wild-type (WT). a Overview of the procedure. Nine PTC organoids were derived and analyzed by histological characterization, DNA-sequencing, and drug sensitivity assays. b Expansion potential of nine PTC organoid cultures. Dots on the graph represent passage, arrows represent continuous expansion. PTC, papillary thyroid cancer; O, organoid. c Representative images of long-term cultured PTC organoids. Organoid cultures were derived from PTC-4_O and PTC-8_O. Scale bar, 100 µm. d Organoid formation efficiency of BRAF V600E PTC organoids and BRAF WT PTC organoids. Data represent the mean ± SEM of organoid number in PTC organoid lines. Scale bar, 100 µm

Article Snippet: Primary antibodies against CK19 (1:200, Cat. No. Kit-0030, Maixin Biotech, China), galectin-3 (1:500, Cat. No. ab76245, Abcam), Ki-67 (1:200, cat. no. ab16667, Abcam), and BRAF (V600E mutant) (1:200, Cat. No. 29002, Cell Signaling Technology) were applied to the sections and incubated overnight at 4 °C.

Techniques: Derivative Assay, Mutagenesis, DNA Sequencing, Cell Culture

Journal: Journal of Translational Medicine

Article Title: Papillary thyroid cancer organoids harboring BRAF V600E mutation reveal potentially beneficial effects of BRAF inhibitor-based combination therapies

doi: 10.1186/s12967-022-03848-z

Figure Lengend Snippet: Immunofluorescence staining of CK19, galectin-3, BRAF V600E , and Ki-67 on PTC organoids and the parental tumors. Passage numbers of PTC organoid lines were: PTC-1_O, P3; PTC-2_O, P3; PTC-3_O, P2; PTC-4_O, P4; PTC-5_O, P3; PTC-6_O, P2; PTC-7_O, P4; PTC-8_O, P3; PTC-9_O, P4. PTC, papillary thyroid cancer. T, parental tumor; O, organoid. Scale bar, 100 µm

Article Snippet: Primary antibodies against CK19 (1:200, Cat. No. Kit-0030, Maixin Biotech, China), galectin-3 (1:500, Cat. No. ab76245, Abcam), Ki-67 (1:200, cat. no. ab16667, Abcam), and BRAF (V600E mutant) (1:200, Cat. No. 29002, Cell Signaling Technology) were applied to the sections and incubated overnight at 4 °C.

Techniques: Immunofluorescence, Staining

Journal: Journal of Translational Medicine

Article Title: Papillary thyroid cancer organoids harboring BRAF V600E mutation reveal potentially beneficial effects of BRAF inhibitor-based combination therapies

doi: 10.1186/s12967-022-03848-z

Figure Lengend Snippet: Histopathological Characteristics of PTC organoids with BRAF V600E mutation or wild-type and their parental tumors. Representative brightfield images of PTC organoids (top), and H&E staining of organoids (middle) and tumor tissues (bottom). Passage numbers of PTC organoid lines were: PTC-1_O, P3; PTC-2_O, P3; PTC-3_O, P2; PTC-4_O, P4; PTC-5_O, P3; PTC-6_O, P2; PTC-7_O, P4; PTC-8_O, P3; PTC-9_O, P4. PTC, papillary thyroid cancer; WT, wild-type. Scale bar, 100 µm

Article Snippet: Primary antibodies against CK19 (1:200, Cat. No. Kit-0030, Maixin Biotech, China), galectin-3 (1:500, Cat. No. ab76245, Abcam), Ki-67 (1:200, cat. no. ab16667, Abcam), and BRAF (V600E mutant) (1:200, Cat. No. 29002, Cell Signaling Technology) were applied to the sections and incubated overnight at 4 °C.

Techniques: Mutagenesis, Staining

Journal: Journal of Translational Medicine

Article Title: Papillary thyroid cancer organoids harboring BRAF V600E mutation reveal potentially beneficial effects of BRAF inhibitor-based combination therapies

doi: 10.1186/s12967-022-03848-z

Figure Lengend Snippet: Sensitivity of PTC-derived organoid lines for BRAF and MEK inhibitors. a Dose–response curves after 5 days of treatment with BRAF and MEK inhibitors. Each data point represents mean ± SEM of 3 independent biological replicates. IC 50 values are calculated and indicated beside the curve graphs. b Scatterplots of the correlation of 1-AUC values for targeted agents and chemotherapeutic drugs screened by two biological replicates (different passages of PTC organoids). Each data point represents 1-AUC for a PTC organoid line treated by the indicated drug. c Drugs with a common target have similar activity profiles across the PTC organoid lines. 1-AUC values are plotted for the inhibitors of BRAF V600E (vemurafenib and dabrafenib) and MEK (selumetinib and trametinib)

Article Snippet: Primary antibodies against CK19 (1:200, Cat. No. Kit-0030, Maixin Biotech, China), galectin-3 (1:500, Cat. No. ab76245, Abcam), Ki-67 (1:200, cat. no. ab16667, Abcam), and BRAF (V600E mutant) (1:200, Cat. No. 29002, Cell Signaling Technology) were applied to the sections and incubated overnight at 4 °C.

Techniques: Derivative Assay, Activity Assay

Journal: Discovery medicine

Article Title: Implementation of Biomarker-Driven Cancer Therapy: Existing Tools and Remaining Gaps

doi:

Figure Lengend Snippet: Selected Examples of Commercially Available Diagnostic Tests Associated Therapy Implication and Relevant Cancer Type.

Article Snippet: Interestingly, over half of these agents are associated with at least one molecular diagnostic test within indicated disease types. table ft1 table-wrap mode="anchored" t5 caption a7 Agent Trade name Target(s) FDA-approved indication(s) Company Monoclonal Antibodies Ado-trastuzumab emtansine (T- DM1) * Kadcyla HER2 Breast cancer (HER2+) * Genentech Bevacizumab Avastin VEGF CRC Genentech GBM NCLC RCC Cetuximab * Erbitux EGFR CRC (KRAS wild-type) * Eli Lilly HNSCC Ipilimumab Yervoy CTLA-4 Melanoma Bristol-Myers Squibb Obinutuzumab Gazyva CD-20 CLL Genentech Panitumumab * Vectibix EGFR CRC (KRAS wild-type) * Amgen Pertuzumab Perjeta HER2 Breast Cancer (HER2+) * Genentech Trastuzumab * Herceptin HER2 Breast cancer (HER2+) * Genentech Gastric cancer (HER2+) * Small Molecule Inhibitors Afatinib * Gilotrif EGFR, HER2 NSCLC (with EGFR exon 19 deletions or L858R substitution) * Boehringer Ingelheim Axitinib Inlyta KIT, PDGFRβ, VEGFR1/2/3 RCC Pfizer Bosutinib * Bosulif ABL CML (Philadelphia chromosome positive) * Pfizer Cabozantinib Cometriq FLT3, KIT, MET, RET, VEGFR2 Medullary thyroid cancer Exelixis Crizotinib * Xalkori ALK, MET NSCLC (with ALK fusion) * Pfizer Dabrafenib * Tafinlar BRAF Melanoma (with BRAF V600E mutation) * GlaxoSmithKline Dasatinib * Sprycel ABL CML (Philadelphia chromosome positive) * Bristol-Myers Squibb ALL (Philadelphia chromosome positive) * Denosumab Xgeva RANKL Giant cell tumor of bone Amgen Erlotinib * Tarceva EGFR NSCLC (with exon 19 deletions or L858R substitutions) * Genentech & OSI Pancreatic cancer Everolimus * Afinitor mTOR Pancreatic neuroendocrine tumor Novartis RCC Breast cancer (ER/PR+) in combination with exemestane * Nonresectable subependymal giant cell astrocytoma associated with tuberous sclerosis Gefitinib Iressa EGFR NSCLC with known prior benefit from gefitinib (limited approval) Astrazeneca Ibrutininb Imbruvica BTK Mantle cell lymphoma Pharmacyclics Imatinib * Gleevec KIT, PDGFR, ABL GI stromal tumor Novartis Dermatofibrosarcoma protuberans Multiple hematologic malignancies including Philadelphia chromosome-positive ALL and CML * Lapatinib * Tykerb HER2, EGFR Breast cancer (HER2+) * GlaxoSmithKline Nilotinib * Tasigna ABL CML (Philadelphia chromosome positive)?

Techniques: Diagnostic Assay, In Situ Hybridization, Mutagenesis, Amplification

Journal: Discovery medicine

Article Title: Implementation of Biomarker-Driven Cancer Therapy: Existing Tools and Remaining Gaps

doi:

Figure Lengend Snippet: US FDA Approved Targeted Therapies and Indications.

Article Snippet: Interestingly, over half of these agents are associated with at least one molecular diagnostic test within indicated disease types. table ft1 table-wrap mode="anchored" t5 caption a7 Agent Trade name Target(s) FDA-approved indication(s) Company Monoclonal Antibodies Ado-trastuzumab emtansine (T- DM1) * Kadcyla HER2 Breast cancer (HER2+) * Genentech Bevacizumab Avastin VEGF CRC Genentech GBM NCLC RCC Cetuximab * Erbitux EGFR CRC (KRAS wild-type) * Eli Lilly HNSCC Ipilimumab Yervoy CTLA-4 Melanoma Bristol-Myers Squibb Obinutuzumab Gazyva CD-20 CLL Genentech Panitumumab * Vectibix EGFR CRC (KRAS wild-type) * Amgen Pertuzumab Perjeta HER2 Breast Cancer (HER2+) * Genentech Trastuzumab * Herceptin HER2 Breast cancer (HER2+) * Genentech Gastric cancer (HER2+) * Small Molecule Inhibitors Afatinib * Gilotrif EGFR, HER2 NSCLC (with EGFR exon 19 deletions or L858R substitution) * Boehringer Ingelheim Axitinib Inlyta KIT, PDGFRβ, VEGFR1/2/3 RCC Pfizer Bosutinib * Bosulif ABL CML (Philadelphia chromosome positive) * Pfizer Cabozantinib Cometriq FLT3, KIT, MET, RET, VEGFR2 Medullary thyroid cancer Exelixis Crizotinib * Xalkori ALK, MET NSCLC (with ALK fusion) * Pfizer Dabrafenib * Tafinlar BRAF Melanoma (with BRAF V600E mutation) * GlaxoSmithKline Dasatinib * Sprycel ABL CML (Philadelphia chromosome positive) * Bristol-Myers Squibb ALL (Philadelphia chromosome positive) * Denosumab Xgeva RANKL Giant cell tumor of bone Amgen Erlotinib * Tarceva EGFR NSCLC (with exon 19 deletions or L858R substitutions) * Genentech & OSI Pancreatic cancer Everolimus * Afinitor mTOR Pancreatic neuroendocrine tumor Novartis RCC Breast cancer (ER/PR+) in combination with exemestane * Nonresectable subependymal giant cell astrocytoma associated with tuberous sclerosis Gefitinib Iressa EGFR NSCLC with known prior benefit from gefitinib (limited approval) Astrazeneca Ibrutininb Imbruvica BTK Mantle cell lymphoma Pharmacyclics Imatinib * Gleevec KIT, PDGFR, ABL GI stromal tumor Novartis Dermatofibrosarcoma protuberans Multiple hematologic malignancies including Philadelphia chromosome-positive ALL and CML * Lapatinib * Tykerb HER2, EGFR Breast cancer (HER2+) * GlaxoSmithKline Nilotinib * Tasigna ABL CML (Philadelphia chromosome positive)?

Techniques: Bioprocessing, Mutagenesis

Journal: Discovery medicine

Article Title: Implementation of Biomarker-Driven Cancer Therapy: Existing Tools and Remaining Gaps

doi:

Figure Lengend Snippet: US FDA Approved Targeted Therapies and Indications.

Article Snippet: Interestingly, over half of these agents are associated with at least one molecular diagnostic test within indicated disease types. table ft1 table-wrap mode="anchored" t5 caption a7 Agent Trade name Target(s) FDA-approved indication(s) Company Monoclonal Antibodies Ado-trastuzumab emtansine (T- DM1) * Kadcyla HER2 Breast cancer (HER2+) * Genentech Bevacizumab Avastin VEGF CRC Genentech GBM NCLC RCC Cetuximab * Erbitux EGFR CRC (KRAS wild-type) * Eli Lilly HNSCC Ipilimumab Yervoy CTLA-4 Melanoma Bristol-Myers Squibb Obinutuzumab Gazyva CD-20 CLL Genentech Panitumumab * Vectibix EGFR CRC (KRAS wild-type) * Amgen Pertuzumab Perjeta HER2 Breast Cancer (HER2+) * Genentech Trastuzumab * Herceptin HER2 Breast cancer (HER2+) * Genentech Gastric cancer (HER2+) * Small Molecule Inhibitors Afatinib * Gilotrif EGFR, HER2 NSCLC (with EGFR exon 19 deletions or L858R substitution) * Boehringer Ingelheim Axitinib Inlyta KIT, PDGFRβ, VEGFR1/2/3 RCC Pfizer Bosutinib * Bosulif ABL CML (Philadelphia chromosome positive) * Pfizer Cabozantinib Cometriq FLT3, KIT, MET, RET, VEGFR2 Medullary thyroid cancer Exelixis Crizotinib * Xalkori ALK, MET NSCLC (with ALK fusion) * Pfizer Dabrafenib * Tafinlar BRAF Melanoma (with BRAF V600E mutation) * GlaxoSmithKline Dasatinib * Sprycel ABL CML (Philadelphia chromosome positive) * Bristol-Myers Squibb ALL (Philadelphia chromosome positive) * Denosumab Xgeva RANKL Giant cell tumor of bone Amgen Erlotinib * Tarceva EGFR NSCLC (with exon 19 deletions or L858R substitutions) * Genentech & OSI Pancreatic cancer Everolimus * Afinitor mTOR Pancreatic neuroendocrine tumor Novartis RCC Breast cancer (ER/PR+) in combination with exemestane * Nonresectable subependymal giant cell astrocytoma associated with tuberous sclerosis Gefitinib Iressa EGFR NSCLC with known prior benefit from gefitinib (limited approval) Astrazeneca Ibrutininb Imbruvica BTK Mantle cell lymphoma Pharmacyclics Imatinib * Gleevec KIT, PDGFR, ABL GI stromal tumor Novartis Dermatofibrosarcoma protuberans Multiple hematologic malignancies including Philadelphia chromosome-positive ALL and CML * Lapatinib * Tykerb HER2, EGFR Breast cancer (HER2+) * GlaxoSmithKline Nilotinib * Tasigna ABL CML (Philadelphia chromosome positive)?

Techniques: Mutagenesis

Journal: Discovery medicine

Article Title: Implementation of Biomarker-Driven Cancer Therapy: Existing Tools and Remaining Gaps

doi:

Figure Lengend Snippet: Selected Examples of Commercially Available Diagnostic Tests Associated Therapy Implication and Relevant Cancer Type.

Article Snippet: Interestingly, over half of these agents are associated with at least one molecular diagnostic test within indicated disease types. table ft1 table-wrap mode="anchored" t5 caption a7 Agent Trade name Target(s) FDA-approved indication(s) Company Monoclonal Antibodies Ado-trastuzumab emtansine (T- DM1) * Kadcyla HER2 Breast cancer (HER2+) * Genentech Bevacizumab Avastin VEGF CRC Genentech GBM NCLC RCC Cetuximab * Erbitux EGFR CRC (KRAS wild-type) * Eli Lilly HNSCC Ipilimumab Yervoy CTLA-4 Melanoma Bristol-Myers Squibb Obinutuzumab Gazyva CD-20 CLL Genentech Panitumumab * Vectibix EGFR CRC (KRAS wild-type) * Amgen Pertuzumab Perjeta HER2 Breast Cancer (HER2+) * Genentech Trastuzumab * Herceptin HER2 Breast cancer (HER2+) * Genentech Gastric cancer (HER2+) * Small Molecule Inhibitors Afatinib * Gilotrif EGFR, HER2 NSCLC (with EGFR exon 19 deletions or L858R substitution) * Boehringer Ingelheim Axitinib Inlyta KIT, PDGFRβ, VEGFR1/2/3 RCC Pfizer Bosutinib * Bosulif ABL CML (Philadelphia chromosome positive) * Pfizer Cabozantinib Cometriq FLT3, KIT, MET, RET, VEGFR2 Medullary thyroid cancer Exelixis Crizotinib * Xalkori ALK, MET NSCLC (with ALK fusion) * Pfizer Dabrafenib * Tafinlar BRAF Melanoma (with BRAF V600E mutation) * GlaxoSmithKline Dasatinib * Sprycel ABL CML (Philadelphia chromosome positive) * Bristol-Myers Squibb ALL (Philadelphia chromosome positive) * Denosumab Xgeva RANKL Giant cell tumor of bone Amgen Erlotinib * Tarceva EGFR NSCLC (with exon 19 deletions or L858R substitutions) * Genentech & OSI Pancreatic cancer Everolimus * Afinitor mTOR Pancreatic neuroendocrine tumor Novartis RCC Breast cancer (ER/PR+) in combination with exemestane * Nonresectable subependymal giant cell astrocytoma associated with tuberous sclerosis Gefitinib Iressa EGFR NSCLC with known prior benefit from gefitinib (limited approval) Astrazeneca Ibrutininb Imbruvica BTK Mantle cell lymphoma Pharmacyclics Imatinib * Gleevec KIT, PDGFR, ABL GI stromal tumor Novartis Dermatofibrosarcoma protuberans Multiple hematologic malignancies including Philadelphia chromosome-positive ALL and CML * Lapatinib * Tykerb HER2, EGFR Breast cancer (HER2+) * GlaxoSmithKline Nilotinib * Tasigna ABL CML (Philadelphia chromosome positive)?

Techniques: Diagnostic Assay, In Situ Hybridization, Mutagenesis, Amplification

Journal: Discovery medicine

Article Title: Implementation of Biomarker-Driven Cancer Therapy: Existing Tools and Remaining Gaps

doi:

Figure Lengend Snippet: US FDA Approved Targeted Therapies and Indications.

Article Snippet: Interestingly, over half of these agents are associated with at least one molecular diagnostic test within indicated disease types. table ft1 table-wrap mode="anchored" t5 caption a7 Agent Trade name Target(s) FDA-approved indication(s) Company Monoclonal Antibodies Ado-trastuzumab emtansine (T- DM1) * Kadcyla HER2 Breast cancer (HER2+) * Genentech Bevacizumab Avastin VEGF CRC Genentech GBM NCLC RCC Cetuximab * Erbitux EGFR CRC (KRAS wild-type) * Eli Lilly HNSCC Ipilimumab Yervoy CTLA-4 Melanoma Bristol-Myers Squibb Obinutuzumab Gazyva CD-20 CLL Genentech Panitumumab * Vectibix EGFR CRC (KRAS wild-type) * Amgen Pertuzumab Perjeta HER2 Breast Cancer (HER2+) * Genentech Trastuzumab * Herceptin HER2 Breast cancer (HER2+) * Genentech Gastric cancer (HER2+) * Small Molecule Inhibitors Afatinib * Gilotrif EGFR, HER2 NSCLC (with EGFR exon 19 deletions or L858R substitution) * Boehringer Ingelheim Axitinib Inlyta KIT, PDGFRβ, VEGFR1/2/3 RCC Pfizer Bosutinib * Bosulif ABL CML (Philadelphia chromosome positive) * Pfizer Cabozantinib Cometriq FLT3, KIT, MET, RET, VEGFR2 Medullary thyroid cancer Exelixis Crizotinib * Xalkori ALK, MET NSCLC (with ALK fusion) * Pfizer Dabrafenib * Tafinlar BRAF Melanoma (with BRAF V600E mutation) * GlaxoSmithKline Dasatinib * Sprycel ABL CML (Philadelphia chromosome positive) * Bristol-Myers Squibb ALL (Philadelphia chromosome positive) * Denosumab Xgeva RANKL Giant cell tumor of bone Amgen Erlotinib * Tarceva EGFR NSCLC (with exon 19 deletions or L858R substitutions) * Genentech & OSI Pancreatic cancer Everolimus * Afinitor mTOR Pancreatic neuroendocrine tumor Novartis RCC Breast cancer (ER/PR+) in combination with exemestane * Nonresectable subependymal giant cell astrocytoma associated with tuberous sclerosis Gefitinib Iressa EGFR NSCLC with known prior benefit from gefitinib (limited approval) Astrazeneca Ibrutininb Imbruvica BTK Mantle cell lymphoma Pharmacyclics Imatinib * Gleevec KIT, PDGFR, ABL GI stromal tumor Novartis Dermatofibrosarcoma protuberans Multiple hematologic malignancies including Philadelphia chromosome-positive ALL and CML * Lapatinib * Tykerb HER2, EGFR Breast cancer (HER2+) * GlaxoSmithKline Nilotinib * Tasigna ABL CML (Philadelphia chromosome positive)?

Techniques: Mutagenesis

Journal: Discovery medicine

Article Title: Implementation of Biomarker-Driven Cancer Therapy: Existing Tools and Remaining Gaps

doi:

Figure Lengend Snippet: Selected Examples of Commercially Available Diagnostic Tests Associated Therapy Implication and Relevant Cancer Type.

Article Snippet: Interestingly, over half of these agents are associated with at least one molecular diagnostic test within indicated disease types. table ft1 table-wrap mode="anchored" t5 caption a7 Agent Trade name Target(s) FDA-approved indication(s) Company Monoclonal Antibodies Ado-trastuzumab emtansine (T- DM1) * Kadcyla HER2 Breast cancer (HER2+) * Genentech Bevacizumab Avastin VEGF CRC Genentech GBM NCLC RCC Cetuximab * Erbitux EGFR CRC (KRAS wild-type) * Eli Lilly HNSCC Ipilimumab Yervoy CTLA-4 Melanoma Bristol-Myers Squibb Obinutuzumab Gazyva CD-20 CLL Genentech Panitumumab * Vectibix EGFR CRC (KRAS wild-type) * Amgen Pertuzumab Perjeta HER2 Breast Cancer (HER2+) * Genentech Trastuzumab * Herceptin HER2 Breast cancer (HER2+) * Genentech Gastric cancer (HER2+) * Small Molecule Inhibitors Afatinib * Gilotrif EGFR, HER2 NSCLC (with EGFR exon 19 deletions or L858R substitution) * Boehringer Ingelheim Axitinib Inlyta KIT, PDGFRβ, VEGFR1/2/3 RCC Pfizer Bosutinib * Bosulif ABL CML (Philadelphia chromosome positive) * Pfizer Cabozantinib Cometriq FLT3, KIT, MET, RET, VEGFR2 Medullary thyroid cancer Exelixis Crizotinib * Xalkori ALK, MET NSCLC (with ALK fusion) * Pfizer Dabrafenib * Tafinlar BRAF Melanoma (with BRAF V600E mutation) * GlaxoSmithKline Dasatinib * Sprycel ABL CML (Philadelphia chromosome positive) * Bristol-Myers Squibb ALL (Philadelphia chromosome positive) * Denosumab Xgeva RANKL Giant cell tumor of bone Amgen Erlotinib * Tarceva EGFR NSCLC (with exon 19 deletions or L858R substitutions) * Genentech & OSI Pancreatic cancer Everolimus * Afinitor mTOR Pancreatic neuroendocrine tumor Novartis RCC Breast cancer (ER/PR+) in combination with exemestane * Nonresectable subependymal giant cell astrocytoma associated with tuberous sclerosis Gefitinib Iressa EGFR NSCLC with known prior benefit from gefitinib (limited approval) Astrazeneca Ibrutininb Imbruvica BTK Mantle cell lymphoma Pharmacyclics Imatinib * Gleevec KIT, PDGFR, ABL GI stromal tumor Novartis Dermatofibrosarcoma protuberans Multiple hematologic malignancies including Philadelphia chromosome-positive ALL and CML * Lapatinib * Tykerb HER2, EGFR Breast cancer (HER2+) * GlaxoSmithKline Nilotinib * Tasigna ABL CML (Philadelphia chromosome positive)?

Techniques: Diagnostic Assay, In Situ Hybridization, Mutagenesis, Amplification

Journal: Discovery medicine

Article Title: Implementation of Biomarker-Driven Cancer Therapy: Existing Tools and Remaining Gaps

doi:

Figure Lengend Snippet: US FDA Approved Targeted Therapies and Indications.

Article Snippet: Interestingly, over half of these agents are associated with at least one molecular diagnostic test within indicated disease types. table ft1 table-wrap mode="anchored" t5 caption a7 Agent Trade name Target(s) FDA-approved indication(s) Company Monoclonal Antibodies Ado-trastuzumab emtansine (T- DM1) * Kadcyla HER2 Breast cancer (HER2+) * Genentech Bevacizumab Avastin VEGF CRC Genentech GBM NCLC RCC Cetuximab * Erbitux EGFR CRC (KRAS wild-type) * Eli Lilly HNSCC Ipilimumab Yervoy CTLA-4 Melanoma Bristol-Myers Squibb Obinutuzumab Gazyva CD-20 CLL Genentech Panitumumab * Vectibix EGFR CRC (KRAS wild-type) * Amgen Pertuzumab Perjeta HER2 Breast Cancer (HER2+) * Genentech Trastuzumab * Herceptin HER2 Breast cancer (HER2+) * Genentech Gastric cancer (HER2+) * Small Molecule Inhibitors Afatinib * Gilotrif EGFR, HER2 NSCLC (with EGFR exon 19 deletions or L858R substitution) * Boehringer Ingelheim Axitinib Inlyta KIT, PDGFRβ, VEGFR1/2/3 RCC Pfizer Bosutinib * Bosulif ABL CML (Philadelphia chromosome positive) * Pfizer Cabozantinib Cometriq FLT3, KIT, MET, RET, VEGFR2 Medullary thyroid cancer Exelixis Crizotinib * Xalkori ALK, MET NSCLC (with ALK fusion) * Pfizer Dabrafenib * Tafinlar BRAF Melanoma (with BRAF V600E mutation) * GlaxoSmithKline Dasatinib * Sprycel ABL CML (Philadelphia chromosome positive) * Bristol-Myers Squibb ALL (Philadelphia chromosome positive) * Denosumab Xgeva RANKL Giant cell tumor of bone Amgen Erlotinib * Tarceva EGFR NSCLC (with exon 19 deletions or L858R substitutions) * Genentech & OSI Pancreatic cancer Everolimus * Afinitor mTOR Pancreatic neuroendocrine tumor Novartis RCC Breast cancer (ER/PR+) in combination with exemestane * Nonresectable subependymal giant cell astrocytoma associated with tuberous sclerosis Gefitinib Iressa EGFR NSCLC with known prior benefit from gefitinib (limited approval) Astrazeneca Ibrutininb Imbruvica BTK Mantle cell lymphoma Pharmacyclics Imatinib * Gleevec KIT, PDGFR, ABL GI stromal tumor Novartis Dermatofibrosarcoma protuberans Multiple hematologic malignancies including Philadelphia chromosome-positive ALL and CML * Lapatinib * Tykerb HER2, EGFR Breast cancer (HER2+) * GlaxoSmithKline Nilotinib * Tasigna ABL CML (Philadelphia chromosome positive)?

Techniques: Mutagenesis